INDIAN COUNCIL OF MEDICAL RESEARCH
Serving the nation since 1911

भारतीय आयुर्विज्ञान अनुसंधान परिषद
स्वास्थ्य अनुसंधान विभाग, स्वास्थ्य एवं परिवार कल्याण मंत्रालय, भारत सरकार

Indian Council of Medical Research
Department of Health Research, Ministry of Health and Family Welfare, Government of India

File No.: 16/18/2024-Admn./e-184719 **Date:** /11/2026

OFFICE MEMORANDUM

Subject: Operational Workflow and Implementation Framework of MedTech Mitra initiative under the Medical Innovations Public-Private Partnerships (MI-PPP) Unit, ICMR-Reg.

In order to provide an integrated and industry-friendly mechanism for identification, evaluation, Intellectual Property protection, technology development, validation, industry partnership, technology transfer and eventual commercialisation of promising medical innovations, the Competent Authority has approved the following operational workflow of MedTech Mitra Initiative under 'Medical Innovations Public-Private Partnerships (MI-PPP) Unit' to streamline its operations.

2. Following operational workflow and implementation framework shall be implemented to take timely operational decisions and facilitate successful outcomes from Public-Private Partnerships by the MI-PPP unit.

2.1 The MI-PPP Unit will be the public facing unit of MedTech Mitra initiative for ICMR. This flagship initiative will be fully coordinated & managed by MI-PPP unit in partnership with different stakeholders including ICMR divisions, knowledge partners and collaborators.

2.2 Applications belonging to different categories of technologies viz. Medical devices & Assistive Technologies, In-vitro Diagnostics, and Therapeutics & Vaccines technologies will be received via a unified Medtech Mitra portal.

2.3 MedTech Mitra applications will be addressed through category-specific Technical Advisory Committee (TAC) meetings each for Medical Device & Assistive Technologies, In-vitro Diagnostics and Therapeutics & Vaccines technologies in a collaborative manner as given below.

Technical Advisory Committee	Concerned ICMR Nodal Team
Medical Devices and Assistive Technologies	Medical Device and Diagnostics Mission Secretariat (MDMS) + MI-PPP
Vaccines and Therapeutics	ICMR-Indian Clinical Trial and Education Network (INTENT) + MI-PPP
In-vitro Diagnostics	ICMR-Communicable Disease Division + MI-PPP

3. MI-PPP unit shall develop, maintain and manage a software-based application management system to capture and track application-wise records, TAC recommendations, and monitor subsequent progress.

4. To ensure timely and effective engagement with public and private partners, the MI-PPP Unit shall schedule and convene TAC meetings on Tuesdays, in consultation with the concerned Divisions/Institutes and experts. In the event that the scheduled meeting day falls on a Government holiday or the meeting cannot be convened due to any official exigency, the meeting shall be rescheduled to the next working day.

5. The MedTech Mitra Workflow is attached at Annexure A and the Composition and Functioning of Technical Advisory Committees are detailed at Annexure B.

6. The MI-PPP Unit shall be responsible for coordinating the implementation of the above framework and undertake necessary follow-up actions.

This issues with the approval of the Competent Authority.

23/11/26

(Jaibir Singh)
Assistant Director General (Admin)

To:

1. Heads/Nodal Officers of concerned Medtech Mitra knowledge partners.
2. Head, Medical Innovations Public-Private Partnerships (MI-PPP) Unit, ICMR.

Copy to:-

1. PS to DG/Addl. DGs/Sr. DDG(A)/Sr. FA, ICMR Hqrs., New Delhi.
2. All Heads of Divisions, ICMR Hqrs.
3. DDG(A)/ADGs/ AO (Admn.), ICMR Hqrs., New Delhi.
4. Dr. M.S. Chalga, Scientist -E with request to upload the same on the ICMR website

वी. रामलिंगस्वामी भवन, पोस्ट बॉक्स नं. 4911,
अंसारी नगर, नई दिल्ली - 110 029, भारत
V. Ramalingaswami Bhawan, P.O. Box No. 4911,
Ansari Nagar, New Delhi - 110 029, India

Tel: +91-11-26588895 / 26588980 / 26589794
+91-11-26589336 / 26588707
Fax: +91-11-26588662 | icmr.nic.in

Annexure A

Medtech Mitra Workflow



23/11/26

File No. MedTech/Mitra/2023/MDMS (Computer No. 173329)
Generated from eOffice by Piyush Dadhich, ASSISTANT(PD)-ICMRHQ, ASSISTANT, ICMR on 19/11/2026 10:09 am

Stage wise application process flow: Each application shall be processed in three stages, as mentioned below:

Stage	Proposed process
Part I — Initial Engagement and Pre-TAC	MI-PPP unit along with the concerned ICMR division and knowledge partners shall assess technology readiness, available evidence and technical gaps, if any. Pre-TAC shall identify the issues requiring TAC advice.
Part II — Technical Advisory Committee (TAC)	Applications found ready at Pre-TAC stage shall be placed before the applicable category-wise TAC for technical advice, and specific, actionable recommendations including funding support.
Part III — Handholding Support	MI-PPP unit shall facilitate the recommended support through designated ICMR nodal teams, knowledge partners and collaborators, and track progress until completion or closure.

23/11/26

****

File No. MedTech/Mitra/2023/MDMS (Computer No. 173329)
Generated from eOffice by Piyush Dadhich, ASSISTANT(PD)-ICMRHQ, ASSISTANT, ICMR on 19/11/2026 10:09 am

Annexure B

Composition and Functioning of Medtech Mitra Technical Advisory Committee (TAC)

TAC shall consist of Core Members, ICMR Division representatives & Technical Experts. The Committee shall broadly consists of Chairperson, Senior officials from MedTech Mitra collaborators, Technical Experts, Nodal officers from ICMR, Knowledge partners and collaborators. The Chairperson shall preside over TAC meetings.

Core Members:

1. CDSCO Officials,
2. Nodal officers from all MedTech Mitra knowledge partners
3. Representative of MI-PPP unit;
4. Head, Development Research

Knowledge Partners:

1. Department of Pharmaceuticals (DoP);
2. ICMR-National Institute for Preclinical Research (ICMR-NIPCR);
3. Atomic Energy Regulatory Board (AERB);
4. Government e-Marketplace (GeM);
5. Andhra Pradesh MedTech Zone (AMTZ);
6. NITI Aayog-Atal Innovation Mission (AIM);
7. Bureau of Indian Standards (BIS);
8. Department of Health Research-Health Technology Assessment in India (DHR-HTAIn)
9. DHR-Centre for Guidelines
10. National Health Systems Resource Centre (NHSRC);

Technical Experts: 3-4 experts relevant to each category.

1. Subject Matter Expert for Medical Devices*
2. Subject Matter Experts for In-vitro Diagnostics;*
3. Subject Matter Experts for Vaccines and Therapeutics;*
4. Subject Matter Experts for Assistive Technologies; *

* The Subject Matter Expert for the concerned application category shall serve as Chairperson, while the Chairperson of the other TAC committee shall participate as members.

Devices & Assistive Technologies (AT)	**Vaccines & Therapeutics (VT)**	**In-vitro Diagnostics**
under MI-PPP unit + MDMS • Chairperson-Devices & AT • Core Members • Member - Chair VT • Member - Chair IVD • Domain specific co-opted Technical Experts • Nodal officer from ICMR	under MI-PPP unit + INTENT • Chairperson-VT • Core Members • Member – Chair-Devices + AT • Member - Chair IVD • Domain specific co-opted Technical Experts • Nodal officer from ICMR	under MI-PPP unit + ICMR-CD • Chairperson-IVD • Core Members • Member - Chair VT • Member - Chair-Devices + AT • Domain specific co-opted Technical Experts • Nodal officer from ICMR

23/11/20

Guiding Principles:

1. The MedTech Mitra shall be coordinated and managed by the MI-PPP Unit in partnership with different stakeholders, including ICMR Divisions, Knowledge partners and Collaborators.

2. The fixed core members and ICMR divisional/institutional representatives shall be common to the three TACs. Each TAC shall additionally draw on technical experts relevant to its category. Applications shall be reviewed for technical readiness, testing/clinical evidence, regulatory/clinical/testing requirements and the most appropriate support pathway.

3. For each TAC mentioned above, the Subject Matter Expert for the concerned application category shall serve as Chairperson, while the Subject Matter Experts appointed as Chair for the other committees shall participate as members. Thus, each TAC shall have only one Chairperson.

4. Chairperson shall be present throughout the meeting, specific experts can be brought-in for discussion on relevant applications.

5. If the nodal officers from knowledge partners or ICMR Divisions are unable to attend the meeting, a senior officer shall be nominated by them to participate in the meetings.

6. The tenure of each committee shall be initially for two years. At least two third technical experts should be present in each meeting to complete the quorum.

7. Nodal officers from ICMR Divisions will provide handholding support to the innovators following TAC recommendations.

8. MI-PPP unit shall circulate the application summary, Pre-TAC observations and supporting documents to all concerned nodal officers and TAC members in advance for the TAC meeting. The MI-PPP Unit shall also prepare and circulate the Minutes of the Meeting (MoM) and coordinate the necessary follow-up actions in accordance with the recommendations of the TAC.

Meeting schedule

One Pre-TAC meeting on Thursday and one TAC meeting on Tuesday shall be convened every month for technologies in each of the three domains: Medical Devices & Assistive Technologies, Vaccines & Therapeutics, and In-Vitro Diagnostics (IVDs), resulting in a total of **three Pre-TAC meetings and three TAC meetings per month.**

The meeting frequency may be increased or decreased, as required, based on the volume of applications and queries received.

In the event that the scheduled meeting day falls on a Government holiday or the meeting cannot be convened due to any official exigency, the meeting shall be rescheduled preferably to the next working day.

23/11/26

****